PRAX
NASDAQPraxis Precision Medicines Inc.
Price$253.44+0.19 (+0.07%)
01:30 PM07:45 PM
News · 26 weeks77-18%
2025-12-142026-06-07
Mix2990d
- Other14(48%)
- SEC Filings7(24%)
- Insider5(17%)
- Analyst1(3%)
- Earnings1(3%)
- Offering1(3%)
Latest news
25 items- PRPraxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare ConferenceBOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET. A live webcast of the event will be available through this link. A replay of the event will also be available on Praxis' "Events and Presentations" website after each event for approximately 180 days. About Praxis Praxis Precision Medicines is a fully integrated, leading centr
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). Th
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Provides Vormatrigine Program UpdatePOWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10% Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ
- INSIDERPrincipal Accounting Officer Mastrocola Lauren was granted 127 shares, increasing direct ownership by 0.94% to 13,573 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERGeneral Counsel and Secretary Nemiroff Alex was granted 78 shares, increasing direct ownership by 0.30% to 26,011 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERChief Financial Officer Kelly Timothy Edwin was granted 121 shares, increasing direct ownership by 0.39% to 31,167 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERChief Operating Officer Sniecinski Megan was granted 89 shares, increasing direct ownership by 0.31% to 28,664 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- INSIDERChief Executive Officer Souza Marcio was granted 126 shares, increasing direct ownership by 0.16% to 77,016 units (SEC Form 4)4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.SCHEDULE 13G - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECSEC Form 10-Q filed by Praxis Precision Medicines Inc.10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsFDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026 EMBRAVE Part A study results showed elsunersen treatment led to a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease-modifying improvements in patients with early-seizure onset SCN2A-DEE Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026 Recruiting completed for relutrigine EMERALD study in broad DEEs, with top
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on May 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 5,420 shares of its common stock to twenty-one new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). Th
- PRPraxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor ConferenceBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026. The Company will host a conference call and a live webcast to review the first quarter financial results and provide a corporate update on Thursday, May 7, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of
- SECSEC Form DEFA14A filed by Praxis Precision Medicines Inc.DEFA14A - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECSEC Form DEF 14A filed by Praxis Precision Medicines Inc.DEF 14A - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorFDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 29, 2027 and is not planning to hold an advisory committee meeting. "Today's announcement brings us one st
- PRPraxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to present 3 oral presentations and 12 posters at AAN 2026Visit Praxis at Booth #2324 for an in-booth speaker showcase featuring Phase 3 Essential3 results for ulixacaltamide, plus scientific exchange on essential tremor. BOSTON, April 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will present expanded analyses from the Phase 3 Essential3 p
- ANALYSTRaymond James initiated coverage on Praxis Precision Medicines with a new price targetRaymond James initiated coverage of Praxis Precision Medicines with a rating of Strong Buy and set a new price target of $815.00
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
PRAX FAQ
7 questionsWhat does Praxis Precision Medicines Inc. do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562...Where does PRAX stock trade?
Praxis Precision Medicines Inc. (PRAX) is listed on NASDAQ.What sector and industry is PRAX in?
Praxis Precision Medicines Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Praxis Precision Medicines Inc. go public?
Praxis Precision Medicines Inc. (PRAX) completed its IPO in 2020.What are analysts saying about PRAX?
Praxis Precision Medicines Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy on 2026-04-10.What companies are similar to PRAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PRAX side-by-side with any of them on Quantisnow.How can I track PRAX on Quantisnow?
Quantisnow aggregates Praxis Precision Medicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRAX to receive live email and push alerts on every new disclosure.